EchoGen fluorocarbon-based ultrasound contrast agent data

At the meeting of the American Society of Echocardiography in Chicago, SNUS presented Phase II results in 60 patients with known or suspected heart disease, showing improved detection of ventricular wall motion and abnormal blood flow in the heart. Doses of the agent ranged from 0.02 to 0.12 ml/kg.

In one study group of 26 patients, full view of the left ventricle cavity was obtained in 86 percent of the patients. Patients without coronary artery disease had normal wall motion, while those with known disease had one or more regional abnormalities. ...